Kidney outcomes using a sustained >= 40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials

Overview

cited authors

Cherney, David Z., I; Dagogo-Jack, Samuel; McGuire, Darren K.; Cosentino, Francesco; Pratley, Richard; Shih, Weichung J.; Frederich, Robert; Maldonado, Mario; Liu, Jie; Wang, Shuai; Cannon, Christopher P.; VERTIS CV Investigators

authors

Pratley, Richard Edwin, MD

Publication Date

June 15, 2021

webpage

Web of Science

published in

CLINICAL CARDIOLOGY Journal

Research

keywords

SGLT2 inhibitor
kidney disease
kidney failure
meta-analysis
randomized clinical trials
type 2 diabetes mellitus

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.